(Q84121992)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425252%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

PCSK9 as a therapeutic target in atherosclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425252%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Ali J Marian

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425252%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

publication date

1 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425252%20AND%20SRC:MED&resulttype=core&format=json

Current Atherosclerosis Reports

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425252%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425252%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425252%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

151-154

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425252%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11883-010-0099-2

1 February 2020

exact match

0 references

cites work

Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor

1 reference

12 December 2020

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

1 reference

12 December 2020

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

1 reference

12 December 2020

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

1 reference

12 December 2020

Nature's genetic gradients and the clinical phenotype

1 reference

12 December 2020

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

1 reference

12 December 2020

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

1 reference

12 December 2020

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

1 reference

12 December 2020

A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis

1 reference

12 December 2020

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

1 reference

12 December 2020

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

1 reference

12 December 2020

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

1 reference

12 December 2020